The first human embryonic stem cell treatment approved by the FDA for human testing has been shown to restore limb function in rats with neck spinal cord injuries – a finding that could expand the clinical trial to include people with cervical damage. In January, the U.S. Food & Drug Administration gave Geron Corp. of Menlo Park, Calif., permission to test the UC Irvine treatment in individuals with thoracic spinal cord injuries, which occur below the neck. However, trying it in those with cervical damage wasn’t approved because preclinical testing with rats hadn’t been completed. Results of the cervical study currently appear online in the journal Stem Cells. UCI scientist Hans Keirstead (pictured) hopes the data will prompt the FDA to authorize clinical testing of the treatment in people with both types of spinal cord damage. About 52 percent of spinal cord injuries are cervical and 48 percent thoracic.